Acadia Pharmaceuticals (ACAD) Operating Leases (2019 - 2026)

Acadia Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $39.0 million for Q1 2026.

• In Q1 2026, Operating Leases fell 12.62% year-over-year to $39.0 million; the TTM figure through Mar 2026 stood at $39.0 million (down 12.62% YoY), while the FY2025 annual figure was $40.6 million, down 3.53% from the prior year.
• Operating Leases for Q1 2026 stood at $39.0 million, down from $40.6 million in the prior quarter.
• The five-year high for Operating Leases was $55.5 million in Q1 2022, with the low at $39.0 million in Q1 2026.
• The 5-year median for Operating Leases is $47.8 million (2023), against an average of $47.3 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases slipped 15.97% in 2024, then rose 6.44% in 2025.
• Acadia Pharmaceuticals' Operating Leases stood at $52.7 million in 2022, then decreased by 9.29% to $47.8 million in 2023, then declined by 12.06% to $42.0 million in 2024, then decreased by 3.53% to $40.6 million in 2025, then slipped by 3.82% to $39.0 million in 2026.
• Business Quant data shows ACAD's Operating Leases at $39.0 million in Q1 2026, $40.6 million in Q4 2025, and $43.0 million in Q3 2025.